Immunome (IMNM)

• Market cap: $2.74B
• 1 day: -1.04%
• 5 days: -2.82%
• 1 month: 17.14%
• 3 months: 55.26%
• 6 months: 130.79%
• Year to date: 19.16%
• 1 year: 136.06%
• 5 years: 44.16%
• 10 years: 84.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Employees: 168